Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. METHODS: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 +/- 5 kg/m(2); HbA(1c): 8.5 +/- 1.2%; 2-h PPG: 245 +/- 65 mg/dL. Patients received exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). RESULTS: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 +/- 6 mg/dL versus 208 +/- 6 mg/dL, p < 0.0001 (evaluable, N = 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 +/- 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by -76 +/- 10 mg/dL. Postprandial glucose parameters (AUC, C(ave), C(max)) were lower with exenatide than sitagliptin (p < 0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 +/- 4 mg/dL vs. -19 +/- 4 mg/dL, p = 0.3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 +/- 0.26, p = 0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 +/- 0.03, p = 0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 +/- 0.04, p = 0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 +/- 0.05, p < 0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 +/- 97 kcal vs. +130 +/- 97 kcal, p = 0.0227, N = 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. CONCLUSIONS: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [176]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“2008 Informa UK - Curr Med Res Opin 2008; 24(10) Exenatilde vs.”
Background(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Research works printed but not linked: 2
- Gedulin B, 2007, Diabetologia, 50, S239
- 2007, Endocr Pract, 13, 3
Cited by
Items 301–384 of 384
Carrington, M. J., Chan, Y., Stewart, S., Sjouke, B., Brazilek, R. J., & Cohen, N. D. (2014) · Internal Medicine Journal · doi:10.1111/imj.12377 · Cited by 4
Nadeau, D. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2215 · Cited by 4
“Recent evidence suggests that pharmacologic levels of GLP-1 receptor agonists provided during treatment are about 4 times higher than the more physiologic levels of GLP-1 achieved with DPP-4 inhibitors.(22) In addition to lowering HbA 1c levels, the other benefi ts of pharmacologic levels of GLP-1 include a regulatory…”
BackgroundIncretin therapy for type 2 diabetes mellitus
Klonoff, D. C. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0077-7 · Cited by 4
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Self-citationCantini, G., Trabucco, M., Dicembrini, I., Mannucci, E., & Luconi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00016-x · Cited by 3
Akiyama, Y., Morita‐Ohkubo, T., Oshitani, N., Ohno, Y., Aso, Y., Inukai, T., Kakei, M., Kawakami, M., Awata, T., Katayama, S., et al. (2015) · Diabetology International · doi:10.1007/s13340-015-0207-1 · Cited by 3
Yang, H. K., Kang, B., Lee, S., Kim, H., Yoon, K., Cha, B., & Cho, J. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.335 · Cited by 3
“[13] reported 2-week treatment of sitagliptin reduced postprandial glucagon secretion relative to baseline in non-Asian subjects.”
BackgroundSharma, M. C., Jain, S. K., & Sharma, R. (2017) · In Silico Pharmacology · doi:10.1007/s40203-017-0032-2 · Cited by 3
“(Havale and Pal 2009; Defronzo et al. 2008) Therefore, the SAR and QSAR studies were mainly focused on the presently available series.”
Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
McIntosh, C. H. S., Kim, S. ‐., Pederson, R. A., Heiser, U. F., & Demuth, H. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch12 · Cited by 3
Rol del enterocito en la dislipemia de la resistencia insulínica
Nogueira, J. P., & Brites, F. D. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.06.009 · Cited by 3
Odegard, P. S., & DeSantis, A. J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4444 · Cited by 3
“com Dovepress slower gastric emptying, and reduced calorie intake.(43) Given the more targeted action of exenatide at mimicking glucagonlike peptide(GLP-1) compared with sitagliptin which impairs breakdown of GLP-1, these results are to be expected.”
Integrating incretin-based therapy into type 2 diabetes management.
Brunton, S. (2013) · PubMed · Cited by 3
Higgins, V., & Adeli, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65897-x · Cited by 3
Silfvergren, O., Rigal, S., Schimek, K. M. S., Simonsson, C., Kanebratt, K. P., Forschler, F., Yesildag, B., Marx, U., Vilén, L., Gennemark, P., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107648 · Cited by 2
Role of enterocytes in dyslipidemia of insulin-resistant states
Nogueira, J. P., & Brites, F. D. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.06.011 · Cited by 2
Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes
Saito, R., & Harada, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00781-y · Cited by 2
“Therefore, a GLP-1 receptor agonists have several glucose lowering effects such as inhibition of gastric emptying and appetite suppression [22].”
Mannucci, E., & Lamanna (2010) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s6345 · Cited by 2
Incretin therapies for type 2 diabetes: what nurses need to know
Capaldi, B. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.7.345 · Cited by 2
A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus
Samat, A., Bhargava, A., & Reddy, V. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3489 · Cited by 2
Ravasio, R. (2011) · Giornale Italiano di Health Technology Assessment · doi:10.1007/bf03320738 · Cited by 2
Nutrition Strategies for Patients on New Incretin Therapies for Type 2 Diabetes
Keen, S., Craven, K., & Kolasa, K. M. (2014) · Nutrition Today · doi:10.1097/nt.0000000000000044 · Cited by 2
“In patients treated with metformin and twice-daily exenatide, the total caloric intake was reduced compared with those taking sitagliptin 100 mg daily.(27)”
MethodExenatide Once Weekly: Opportunities in the Primary Care Setting
Davidson, J. A., Nikkei, C., & Grimm, M. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2662 · Cited by 2
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes
Corsino, L., Cox, M. E., Rowell, J. V., & Green, J. B. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2109 · Cited by 2
New developments in incretin‐based therapies: The current state of the field
Robertson, C. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00453.x · Cited by 2
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
Liraglutide: can it make a difference in the treatment of type 2 diabetes?
Unger, J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02497.x · Cited by 1
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes
Rizzo, M., TOMKIN, G. H., Angelo, M. P., Pepe, I., Maria, R. V., Rosa, S. D., Giovam, B. R., & Fede, G. D. (2011) · Clinical Lipidology · doi:10.2217/clp.11.46 · Cited by 1
Bloomgarden, Z. T. (2010) · Endocrine Practice · doi:10.4158/ep.16.s2.1 · Cited by 1
Bellman, S. M., & Aromataris, E. (2014) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2014-1858 · Cited by 1
Advances in pharmacotherapy of Type 2 diabetes (Part-3: The gliptins)
Elhadd, T. A., Ghosh, S. K., Collier, A., & Sudan, K. (2010) · Cited by 1
Pancreatic Beta Cells in Metabolic Syndrome
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., Sánchez-Soto, C., Albarado-Ibáñez, A., Chávez‐Maldonado, J. P., Toledo, A., & García-Delgado, N. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_27-2 · Cited by 1
Joy, S. V., Freeman, J. S., & LaSalle, J. R. (2011) · Osteopathic Family Physician · doi:10.1016/j.osfp.2011.07.002 · Cited by 1
Inkretine: Gibt es kardiovaskuläre Effekte?
Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials
Doggrell, S. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.576671 · Cited by 1
“is more potent than sitagliptin at reducing postprandial glucose [61].”
BackgroundBailey, T. S. (2011) · US Endocrinology · doi:10.17925/use.2011.07.02.82 · Cited by 1
Pharmacology of the GLP-1 Analog Liraglutide in Healthy Cats
Hall, M. J. (2014) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
The Physiology and Pharmacology of Diabetic Gastropathy Management
Dolan, R. D., Rohani, T. S., Muttineni, D., & Mashimo, H. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00045-1 · Cited by 1
Sesti, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01072.x · Cited by 1
Akiyama, Y., Morita‐Ohkubo, T., Oshitani, N., Ohno, Y., Aso, Y., Inukai, T., Kakei, M., Kawakami, M., Awata, T., Katayama, S., et al. (2017) · Diabetology International · doi:10.1007/s13340-017-0322-2 · Cited by 1
Inhibition de la sécrétion du glucagon par les agonistes du GLP-1 et les inhibiteurs de la DPP-4
Hansen, M. V., Knop, F. K., Hare, K. J., & Holst, J. J. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70207-3 · Cited by 2
Vergel, M. A., Salas Paredes, A., Buela S., L. M., Valeri, L., Arata de Bellabarba, G., & Velázquez-Maldonado, E. (2013) · SaberULA (Universidad de Los Andes) · Cited by 1
Nogueira, J. P. (2011) · theses.fr (ABES) · doi:10.70675/884e6bfaz8512z425fz8fc6z9fce492e511d · Cited by 1
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Clinical effects of the GLP-1 receptor agonist exenatide in patients with type 2 diabetes
Bunck, M. C. M. (2011) · Pure Amsterdam UMC
Incretin-based therapies for type 2 diabetes
Capaldi, B. (2012) · Practice Nursing · doi:10.12968/pnur.2012.23.10.508
Monte, S. V., Schentag, J. J., Adelman, M. H., & Paladino, J. A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400220
Incretin-based therapies for type 2 diabetes: a nurse’s perspective
Hodgkiss, J. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.21.79997
Meece, J. D., Pearson, T. L., & Siminerio, L. M. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714527802
“Basal insulin, which targets fasting plasma glucose levels, would complement the short-acting exenatide, which tends to primarily affect postprandial glucose levels.(15,16)”
BackgroundWeekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies
Micale, S. J., Khatounabadi, S., Kane, M. P., Busch, R. S., Bakst, G., Abelseth, J. M., & Hamilton, R. A. (2014) · Journal of Pharmacy Technology · doi:10.1177/8755122513518189
“In addition, GLP-1 therapy is associated with greater reductions in hemoglobin A1C and body weight compared with the dipeptidyl peptidase-4 inhibitors.(12,13) Longer-acting GLP-1 analogs have been associated with better glycemic control and patient tolerability compared with the use of shorter-acting GLP-1 analogs.”
BackgroundExenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors
Htike, Z. Z., Khunti, K., & Davies, M. J. (2012) · Clinical Practice · doi:10.2217/cpr.11.132
Clinical Use of Incretin-Based Therapy in Type 2 Diabetes Mellitus
Shomali, M. E. (2011)
Pharmacologic Approach to Type 2 Diabetes in Obese Patients
Litwak, L., Musso, C., & Fuentes, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_10
Widenmaier, S. B. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071070
“Furthermore, subcutaneous administration of a GLP-1R agonist was found to reduce food intake (DeFronzo et al., 2008) and intravenous or subcutaneous injections of GLP-1 resulted in profound reductions in appetite and caloric intake in humans (Flint et al., 1998; Verdich et al., 2001).”
BackgroundScheen, A. J. (2012) · ORBi (University of Liège)
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Self-citationThe Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era
Kendall, D. M. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42866-6
Pancreatic b Cells in Metabolic Syndrome 30
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., & Toledo, A. (2015)
Paracrine regulation of glucagon secretion from pancreatic islets
Elliott, A. D. (2014)
Nausea, Vomiting, and Hormonal Disorders
Calles-Escandón, J., & Pasten, H. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-34076-0_6
Sitagliptin Review of its Use in the Management of Type 2
Åhrén, B., Barnett, A. H., Eriksson, J. G., Mohan, V., Nilsson, P. M., Raz, I., & Yeap, B. B. (2010)
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
Nutrient and Hormonal Regulation of Systemic Lipid and Glucose Handling
Snook, L. A. (2016) · The Atrium (University of Guelph)
Glucagon-like peptide (GLP)-1 analogues for normoglycaemic, overweight or obese adults
Mazzucca, A. C. P., Parra, M. T., Latorraca, C. O., Spinola‐Castro, A. M., & Riera, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012793
RetractedVascular Adverse Events Associated with Sitagliptin Agent in Taiwan: A Drug Evaluation Report
Yen, Y.-H. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.02.000815
New pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
Musso, C., Litwak, L., & Sinay, I. R. (2014) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v48i1.179
Galindo, D. E. B. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/12798
The pathophysiology of gut–liver connection
Maroni, L., Fianchi, F., Miele, L., & Svegliati‐Baroni, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00002-4
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
Regional Intestinal Drug Absorption
Gonzalez-Alvarez, M. I., & Dahan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3657-6
Do Many People with Type 2 Diabetes Really Need Insulin?
Schwartz, S. S. (2015) · doi:10.2337/9781580405713.case66
Bojic, L. A. (2013) · Scholarship@Western (Western University)
High throughput in situ cell signalling study on the microfluidic platform
Wu, X. (2017) · FreiDok plus (Universitätsbibliothek Freiburg) · doi:10.6094/unifr/13097
Effetti endocrino-metabolici dell'exenatide in pazienti obesi non diabetici
PARDO, M. A. (2015) · Electronic Theses and Dissertations Repository (University of Pisa)
Xie, C. (2021) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Kim, H., Chae, J. H., & Moon, H. Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02141-z
“Exenatide was the fi rst short-acting GLP-1 RA approved for weight management by enhancing satiety [5].”
Treatment of hyperphagia and obesity in Prader–Willi syndrome
Höybye, C., Forster, J. L., Goldstone, A. H., Gourash, L. M., Miller, J., & Tauber, M. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70173
Metadata
- Authors
- DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA
- Eli Lilly (United States) (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- DeFronzo, Ralph A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-09-10
- Volume
- 24
- Issue
- 10
- Pages
- 2943-2952
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2159198773
- Cited by
- 373
- References
- 33
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 14 · 2019: 7 · 2018: 12 · 2017: 19 · 2016: 20 · 2015: 23 · 2014: 38 · 2013: 36 · 2012: 40
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sitagliptin, type 2 diabetes, postprandial blood glucose, insulin secretion, glucagon secretion, gastric emptying, energy intake, GLP-1 receptor agonists, DPP-4 inhibitors, insulinogenic index, metformin, glycemic control, drug comparison, fasting blood glucose
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Insulin Secretion, Blood Glucose, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Stomach, Triazoles, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.